Congress Asset Management Co. Increases Holdings in Repligen Co. (NASDAQ:RGEN)

Congress Asset Management Co. boosted its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 10.8% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 129,219 shares of the biotechnology company's stock after acquiring an additional 12,599 shares during the quarter. Congress Asset Management Co. owned about 0.23% of Repligen worth $16,442,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in RGEN. Signaturefd LLC lifted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. bought a new position in shares of Repligen in the fourth quarter valued at $29,000. Raiffeisen Bank International AG purchased a new position in shares of Repligen in the fourth quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new position in Repligen in the 4th quarter worth approximately $40,000. Finally, Global Retirement Partners LLC grew its holdings in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after buying an additional 129 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of several analyst reports. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a research note on Tuesday, April 29th. JPMorgan Chase & Co. decreased their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Wall Street Zen raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Finally, Canaccord Genuity Group cut their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $173.25.

Insider Buying and Selling

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by company insiders.

Repligen Trading Down 0.7%

NASDAQ:RGEN traded down $0.92 on Wednesday, reaching $131.96. 378,770 shares of the stock traded hands, compared to its average volume of 746,912. Repligen Co. has a 1-year low of $102.97 and a 1-year high of $182.52. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company's 50 day moving average is $127.51 and its 200-day moving average is $143.27. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of -258.74, a price-to-earnings-growth ratio of 4.54 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. During the same period in the prior year, the business earned $0.28 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.